Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and
activities of transcriptional factors involved in both cancer initiation and progression through …

Histone deacetylases (HDACs) are expressed at increased levels in cells of various
malignancies, and the use of HDAC inhibitors has improved outcomes in patients with …

Histone deacetylase (HDAC) inhibitors are emerging as promising anticancer drugs.
Because aberrant activity and expression of HDACs have been implicated in various cancer …

Histone deacetylase (HDAC) inhibitors are a new group of anticancer agents that have a
potential role in the regulation of gene expression, induction of cell death, apoptosis and cell …

Histone deacetylases (HDACs) regulate the acetylation of a variety of histone and
nonhistone proteins, controlling the transcription and regulation of genes involved in cell …

This review focuses on the discovery and development of the histone deacetylase (HDAC)
inhibitor, suberoylanilide hydroxamic acid (SAHA). Post-translational modifications of the …

The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically
well established as attractive therapeutic targets. During investigation of trends within …

Histone deacetylase (HDAC) inhibitors are an exciting new addition to the arsenal of cancer
therapeutics. The inhibition of HDAC enzymes by HDAC inhibitors shifts the balance …

Importance of the field: Histone deacetylase (HDAC) inhibitors are being developed as a
new, targeted class of anticancer drugs. Area covered in this review: This review focuses on …

Cancer is as much an epigenetic disease as it is a genetic and cytogenetic disease. The
discovery that drastic changes in DNA methylation and histone modifications are commonly …